Breast cancer treatment options
Pro Research Analysisby 
Searched over 200M research papers
Breast Cancer Treatment Options: Overview and Key Modalities
Breast cancer treatment has become increasingly personalized, with options tailored to the cancer’s subtype, stage, and molecular characteristics. The main treatment modalities include surgery, radiation therapy, chemotherapy, endocrine (hormone) therapy, targeted therapy, and immunotherapy. The choice and combination of these treatments depend on individual patient and tumor factors Loibl2021Trayes2021Peart2015+2 MORE.
Surgery and Radiation Therapy in Breast Cancer
Surgery is often the first step for early-stage breast cancer and includes options such as lumpectomy (removal of the tumor and some surrounding tissue) or mastectomy (removal of the entire breast). Both approaches can offer similar survival rates when the tumor can be completely excised Trayes2021Peart2015. Sentinel lymph node biopsy is commonly performed to check for cancer spread .
Radiation therapy is typically used after breast-conserving surgery (lumpectomy) and sometimes after mastectomy, especially if there is a higher risk of recurrence. Modern radiotherapy techniques aim to minimize exposure to the heart, lungs, and esophagus to reduce long-term risks Kerr2022Loibl2021Peart2015.
Chemotherapy: Systemic Treatment for Various Subtypes
Chemotherapy is a cornerstone for many breast cancer patients, especially those with higher-risk or triple-negative breast cancer (TNBC). Common agents include anthracyclines (doxorubicin, epirubicin), taxanes (paclitaxel, docetaxel), and others like capecitabine and platinum compounds Kerr2022Trayes2021Roskoski2024+1 MORE. Chemotherapy can be given before surgery (neoadjuvant) to shrink tumors or after surgery (adjuvant) to reduce recurrence risk Kerr2022Loibl2021Trayes2021.
Endocrine (Hormone) Therapy for Hormone Receptor-Positive Breast Cancer
For tumors that express estrogen or progesterone receptors (ER/PR-positive), endocrine therapy is a mainstay. Options include selective estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), and ovarian suppression or ablation in premenopausal women. Treatment typically lasts 5–10 years Kerr2022Loibl2021Trayes2021+1 MORE.
Targeted Therapies: HER2-Positive and Beyond
HER2-positive breast cancers benefit from targeted therapies such as trastuzumab, pertuzumab, trastuzumab emtansine, and neratinib. These drugs specifically block the HER2 protein, which drives cancer growth in this subtype Kerr2022Loibl2021Roskoski2024+2 MORE. For metastatic disease, additional targeted agents like CDK4/6 inhibitors, PI3K inhibitors, and PARP inhibitors are used based on the tumor’s molecular profile Loibl2021Roskoski2024Lau2022.
Immunotherapy and Newer Approaches
Immunotherapy, particularly immune checkpoint inhibitors like atezolizumab and pembrolizumab (Keytruda), has shown promise in triple-negative breast cancer, especially when combined with chemotherapy Loibl2021Wang2022Mandapati2022+2 MORE. Antibody-drug conjugates and other novel agents are also being developed to target specific pathways and improve outcomes Lau2022Burguin2021.
Combination Therapies and Personalized Medicine
Combination therapies—using two or more drugs targeting different pathways—are increasingly common, especially for aggressive or resistant cancers. These combinations can be more effective and sometimes less toxic than single-agent treatments Wang2022Lau2022Burguin2021. Personalized treatment plans are based on molecular and genetic testing, including markers like ER, PR, HER2, BRCA1/2, and PIK3CA Loibl2021Roskoski2024Burguin2021.
Special Considerations: Triple-Negative Breast Cancer (TNBC)
TNBC lacks ER, PR, and HER2, making it more challenging to treat. Standard options include chemotherapy (taxanes, anthracyclines), but newer treatments like PARP inhibitors, immunotherapy, and antibody-drug conjugates are expanding options for these patients Mandapati2022Lau2022Burguin2021.
Risks, Side Effects, and Resistance
While most treatments reduce breast cancer mortality and recurrence, some increase the risk of other health problems. For example, anthracyclines and certain radiotherapy techniques can raise the risk of heart disease and secondary cancers. Resistance to conventional therapies is also a challenge, leading to ongoing research into drug repurposing and new treatment strategies Kerr2022Costa2020Burguin2021.
Conclusion
Breast cancer treatment is multifaceted and increasingly personalized, involving surgery, radiation, chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. The choice of treatment depends on cancer subtype, stage, and molecular features, with ongoing research focused on improving outcomes and reducing side effects for all patients Kerr2022Loibl2021Trayes2021+6 MORE.
Sources and full results
Most relevant research papers on this topic
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer mortality by 10-25%, but may increase non-breast cancer mortality.
Breast Cancer Treatment.
Breast cancer treatment varies based on the stage, with preoperative endocrine therapy, surgical options, and postoperative radiation, endocrine therapy, immunotherapy, and chemotherapy.
Triple negative breast cancer: approved treatment options and their mechanisms of action
FDA-approved therapies like Trodelvy, olaparib, and Keytruda are effective in treating triple-negative breast cancer, with potential for future advancements in drug delivery methods.
Understanding Breast cancer: from conventional therapies to repurposed drugs.
Repurposing existing drugs can potentially improve breast cancer treatment efficacy and reduce resistance, offering safer and more tolerable treatments for patients.
DOI